瑞科生物-B股票讨论区

因为没有产品商业化，缺乏盈利，以及渐渐丧失的市场流动性，瑞科生物的前景存在不确定性。瑞科生物面临的挑战包括加速疫苗项目的商业化进程，提高现金流，以及提高投资者对其的关注度。

Specifically, a second booster shot will be administered to people from high-risk groups, citizens older than 60, patients with chronic fundamental diseases and those with compromised immune systems. 
Hong Kong-listed vaccine makers, buoyed by the news, broadly shot up. $康希诺生物(06185.HK)$rose 6.6% to $90.6, on a volume of 9.0554 million shares, involving $801 million. $瑞科生物-B(02179.HK)$ , $诺诚健华(09969.HK)$ and ...